Richard S. Levy - 29 May 2026 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Reporting relationship: Director
Issuer ticker: KNSA
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 16:44:23 UTC
Prior SEC filing: 22 May 2026
Next SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Douglas Barry, Attorney-in-Fact

Key filing fact

Richard S. Levy filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 02 Jun 2026.

Key facts

This page summarizes Richard S. Levy's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 16:44.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001454983 Primary reporting owner

Levy Richard S

Relationship: Director
Address: C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM
Signature: /s/ Douglas Barry, Attorney-in-Fact
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares: +2,799
Change %: +15%
Price
Shares after: 21,956
Date: 29 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value
Shares: +12,158
Change %
Price: $0.000000^*
Shares after: 12,158
Date: 29 May 2026
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 12,158
Exercise price: $48.38
Footnotes: F2

KNSA transaction Derivative

Restricted Share Units

Award

Transaction value
Shares: +2,026
Change %
Price: $0.000000^*
Shares after: 2,026
Date: 29 May 2026
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 2,026
Exercise price
Footnotes: F1, F3

KNSA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -2,799
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 2,799
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Footnote F2

The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Footnote F3

The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.

Footnote F4

The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.